École normale supérieure de Paris, 45, rue D'Ulm, 75005 Paris, France; Department of Human Medicine, Faculty of Health, Witten-Herdecke University, 58453 Witten, Germany.
Université de Paris, INSERM, IAME, 75006 Paris, France.
Infect Dis Now. 2021 Feb;51(1):7-13. doi: 10.1016/j.medmal.2020.09.013. Epub 2020 Oct 3.
Efficient therapeutic strategies are needed to counter the COVID-19 pandemic, caused by the SARS-CoV-2 virus. In a context where specific vaccines are not yet available, the containment of the pandemic would be facilitated with efficient prophylaxis. We screened several clinical trials repositories and platforms in search of the prophylactic strategies being investigated against COVID-19 in July 2020. Up to July 5, 2020, only one clinical trial result was published, although we found 112 clinical trial protocols targeting medical workers (n=70, 63%), patients relatives (n=20, 18%) or individuals at risk of severe COVID-19 (n=14, 13%). (Hydroxy)chloroquine was the most frequently evaluated treatment (n=69, 62%), before BCG vaccine (n=12, 11%), this followed by numerous antivirals and immune enhancers. Ninety-eight (88%) clinical trials were randomized with a median of planned inclusions of 530 (IQR 258-1299). Both pre- and post-exposure prophylaxes are investigated.
需要有效的治疗策略来应对由 SARS-CoV-2 病毒引起的 COVID-19 大流行。在尚未有特定疫苗的情况下，有效的预防措施将有助于控制大流行。我们在 2020 年 7 月搜索了几个临床试验存储库和平台，以寻找针对 COVID-19 的预防策略。截至 2020 年 7 月 5 日，仅公布了一项临床试验结果，尽管我们发现了 112 项针对医务人员（n=70，63%）、患者亲属（n=20，18%）或有 COVID-19 严重风险的个体（n=14，13%）的临床试验方案。（羟基）氯喹是评估最多的治疗方法（n=69，62%），其次是卡介苗疫苗（n=12，11%），其次是许多抗病毒药物和免疫增强剂。98 项（88%）临床试验为随机试验，计划纳入中位数为 530 例（IQR 258-1299）。都在研究暴露前和暴露后的预防。
